DK3743420T3 - Heterocyclylamino-substituerede triazoler som modulatorer af rho-associeret proteinkinase - Google Patents
Heterocyclylamino-substituerede triazoler som modulatorer af rho-associeret proteinkinase Download PDFInfo
- Publication number
- DK3743420T3 DK3743420T3 DK19702694.1T DK19702694T DK3743420T3 DK 3743420 T3 DK3743420 T3 DK 3743420T3 DK 19702694 T DK19702694 T DK 19702694T DK 3743420 T3 DK3743420 T3 DK 3743420T3
- Authority
- DK
- Denmark
- Prior art keywords
- kinaches
- heterocyclylamino
- rho
- modulators
- associated protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1801226.0A GB201801226D0 (en) | 2018-01-25 | 2018-01-25 | Modulators of Rho-associated protein kinase |
| PCT/GB2019/050215 WO2019145729A1 (en) | 2018-01-25 | 2019-01-25 | Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3743420T3 true DK3743420T3 (da) | 2022-03-07 |
Family
ID=61558335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19702694.1T DK3743420T3 (da) | 2018-01-25 | 2019-01-25 | Heterocyclylamino-substituerede triazoler som modulatorer af rho-associeret proteinkinase |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11497751B2 (da) |
| EP (2) | EP3743420B1 (da) |
| JP (2) | JP2021512158A (da) |
| KR (1) | KR20200113216A (da) |
| CN (1) | CN111655681B (da) |
| AU (1) | AU2019213214B2 (da) |
| BR (1) | BR112020013759A2 (da) |
| CA (1) | CA3088330A1 (da) |
| CY (1) | CY1125017T1 (da) |
| DK (1) | DK3743420T3 (da) |
| EA (1) | EA202091711A1 (da) |
| ES (1) | ES2907833T3 (da) |
| GB (1) | GB201801226D0 (da) |
| HR (1) | HRP20220269T8 (da) |
| HU (1) | HUE058940T2 (da) |
| IL (1) | IL275988B2 (da) |
| LT (1) | LT3743420T (da) |
| MX (1) | MX2020007898A (da) |
| PH (1) | PH12020550986A1 (da) |
| PL (1) | PL3743420T3 (da) |
| PT (1) | PT3743420T (da) |
| SG (1) | SG11202006087UA (da) |
| SI (1) | SI3743420T1 (da) |
| WO (1) | WO2019145729A1 (da) |
| ZA (1) | ZA202003983B (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201801226D0 (en) | 2018-01-25 | 2018-03-14 | Redx Pharma Plc | Modulators of Rho-associated protein kinase |
| CN111718310B (zh) * | 2019-08-19 | 2021-06-11 | 中国药科大学 | 苯基取代的五元杂环类化合物及其制备方法、用途和药物组合物 |
| CN110845410B (zh) * | 2019-10-29 | 2021-02-26 | 暨明医药科技（苏州）有限公司 | 一种一锅法制备6,7-二甲氧基-3,4-二氢异喹啉盐酸盐的方法 |
| CA3226387A1 (en) * | 2021-07-26 | 2023-02-02 | Joel D. Moore | Rock2 inhibitors and uses thereof |
| CN113999211B (zh) * | 2021-11-23 | 2022-11-29 | 郑州大学 | 一类特异性抗前列腺癌活性的含1,2,3-三氮唑的吲唑骨架衍生物 |
| GB202200735D0 (en) * | 2022-01-20 | 2022-03-09 | Redx Pharma Plc | Compounds |
| WO2023182856A1 (ko) * | 2022-03-24 | 2023-09-28 | 서울대학교산학협력단 | 로-키나제 억제제를 포함하는 켈로이드 등 피부 섬유화 질환의 예방 또는 치료용 약학적 조성물 및 그의 용도 |
| CN116891460A (zh) * | 2023-07-12 | 2023-10-17 | 浙江大学 | 一种吲唑类衍生物或其药用盐及应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9207396D0 (en) | 1992-04-03 | 1992-05-13 | Merck Sharp & Dohme | Therapeutic agents |
| CA2422367C (en) * | 2000-09-15 | 2010-05-18 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| CL2003002353A1 (es) * | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
| WO2004052280A2 (en) * | 2002-12-10 | 2004-06-24 | Imclone Systems Incorporated | Anti-angiogenic compounds and their use in cancer treatment |
| JP2007530589A (ja) * | 2004-03-26 | 2007-11-01 | アンフォラ ディスカバリー コーポレーション | 特定のトリアゾールを基礎とする化合物、組成物、およびそれらの使用 |
| WO2006135383A2 (en) | 2004-08-04 | 2006-12-21 | Myriad Genetics, Inc. | Indazoles |
| WO2007139967A2 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| DE102007022565A1 (de) * | 2007-05-14 | 2008-11-20 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
| US8344144B2 (en) * | 2008-06-18 | 2013-01-01 | Merck Sharp & Dohme Corp. | Inhibitors of Janus kinases |
| CN102884060B (zh) * | 2010-03-24 | 2019-07-19 | 阿米泰克治疗方案公司 | 用于抑制激酶的杂环化合物 |
| WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| US9073892B2 (en) * | 2010-12-20 | 2015-07-07 | Merck Serono S.A. | Indazolyl triazol derivatives |
| KR20140131955A (ko) * | 2012-03-09 | 2014-11-14 | 카나 바이오사이언스 인코포레이션 | 신규 트리아진 유도체 |
| EP3262041A4 (en) * | 2015-02-27 | 2018-08-01 | Lycera Corporation | Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease |
| UA127863C2 (uk) | 2015-12-16 | 2024-01-31 | Локсо Онколоджі, Інк. | Сполуки, які можна застосовувати як інгібітори кінази |
| KR102469161B1 (ko) * | 2017-06-30 | 2022-11-23 | 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 | Ｒｈｏ-관련 단백질 키나아제 억제제, Ｒｈｏ-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도 |
| GB201801226D0 (en) | 2018-01-25 | 2018-03-14 | Redx Pharma Plc | Modulators of Rho-associated protein kinase |
-
2018
- 2018-01-25 GB GBGB1801226.0A patent/GB201801226D0/en not_active Ceased
-
2019
- 2019-01-25 SG SG11202006087UA patent/SG11202006087UA/en unknown
- 2019-01-25 PL PL19702694T patent/PL3743420T3/pl unknown
- 2019-01-25 PT PT197026941T patent/PT3743420T/pt unknown
- 2019-01-25 SI SI201930178T patent/SI3743420T1/sl unknown
- 2019-01-25 EA EA202091711A patent/EA202091711A1/ru unknown
- 2019-01-25 CA CA3088330A patent/CA3088330A1/en active Pending
- 2019-01-25 JP JP2020561950A patent/JP2021512158A/ja active Pending
- 2019-01-25 EP EP19702694.1A patent/EP3743420B1/en active Active
- 2019-01-25 LT LTEPPCT/GB2019/050215T patent/LT3743420T/lt unknown
- 2019-01-25 HR HRP20220269TT patent/HRP20220269T8/hr unknown
- 2019-01-25 BR BR112020013759-6A patent/BR112020013759A2/pt unknown
- 2019-01-25 KR KR1020207022578A patent/KR20200113216A/ko not_active Application Discontinuation
- 2019-01-25 EP EP21214072.7A patent/EP4026834A1/en active Pending
- 2019-01-25 HU HUE19702694A patent/HUE058940T2/hu unknown
- 2019-01-25 WO PCT/GB2019/050215 patent/WO2019145729A1/en active Application Filing
- 2019-01-25 ES ES19702694T patent/ES2907833T3/es active Active
- 2019-01-25 MX MX2020007898A patent/MX2020007898A/es unknown
- 2019-01-25 AU AU2019213214A patent/AU2019213214B2/en active Active
- 2019-01-25 US US16/964,904 patent/US11497751B2/en active Active
- 2019-01-25 DK DK19702694.1T patent/DK3743420T3/da active
- 2019-01-25 CN CN201980010083.3A patent/CN111655681B/zh active Active
-
2020
- 2020-06-25 PH PH12020550986A patent/PH12020550986A1/en unknown
- 2020-06-30 ZA ZA2020/03983A patent/ZA202003983B/en unknown
- 2020-07-12 IL IL275988A patent/IL275988B2/en unknown
-
2022
- 2022-02-16 CY CY20221100132T patent/CY1125017T1/el unknown
- 2022-08-26 US US17/896,626 patent/US11878020B2/en active Active
-
2023
- 2023-11-28 JP JP2023200631A patent/JP2024026193A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3743420T3 (da) | Heterocyclylamino-substituerede triazoler som modulatorer af rho-associeret proteinkinase | |
| DK3774791T3 (da) | Heterocykliske forbindelser som immunmodulatorer | |
| DK3788040T3 (da) | Pyridazinoner som parp7-inhibitorer | |
| DK3704120T3 (da) | Heterocykliske forbindelser som prmt5-inhibitorer | |
| DK3442980T3 (da) | Heterocykliske forbindelser som ret-kinase-hæmmere | |
| DK3572416T3 (da) | Diaryl-makrocykler som modulatorer af proteinkinaser | |
| DK3687994T3 (da) | Gadolinium-bærende pcta-baserede kontrastmidler | |
| MA49908A (fr) | Composés inhibant la protéine mcl-1 | |
| DK3724190T3 (da) | Substituerede bicykliske heterocykliske forbindelser som PRMT5 inhibitorer | |
| DK3743406T3 (da) | Tmem16a modulatorer | |
| DK3466934T3 (da) | Sulfonamidforbindelser eller salt deraf som ribonukleotidreductase-inhibitorer til behandling af kræft | |
| DK3288405T3 (da) | Kemisk minimeret system til tidsreduceret påsætning af øjenvippeforlængelser | |
| DK3157929T3 (da) | Pyrazolforbindelser som modulatorer af fshr og anvendelser deraf | |
| DK3512857T3 (da) | Spiro-bicykliske inhibitorer af menin-mll-interaktion | |
| DK3749669T3 (da) | Ahr-modulatorer | |
| MA50174A (fr) | Formules de protéines de fusion vegfr-fc | |
| DK3670499T3 (da) | Pyrazolderivater, der er anvendelige som inhibitorer af 5-lipoxygenase-aktiverende protein (flap) | |
| DK3414517T3 (da) | Holografisk karakterisering af proteinaggregater | |
| DE112019002443A5 (de) | Applikator | |
| DK3551188T3 (da) | Substituerede quinazolinsulfonamider som hæmmere af thioredoxin-interagerende protein (txnip) | |
| DK3280407T3 (da) | Anvendelse af isothiocyanatderivater som modulatorer af perifere og neuropatiske smerter | |
| ES1224261Y (es) | Aplicador de liquidos | |
| UA39602S (uk) | Комплект етикеток | |
| DK3638686T3 (da) | Peptidylketoamider som inhibitorer af rombeformede proteaser | |
| UA38661S (uk) | Комплект етикеток |